Coeptis Therapeutics (NASDAQ:ZSQR) Stock Price Down 6.3% – Here’s Why

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR)’s stock price traded down 6.3% during mid-day trading on Monday . The stock traded as low as $11.67 and last traded at $11.67. 397,179 shares were traded during mid-day trading, an increase of 106% from the average daily volume of 192,465 shares. The stock had previously closed at $12.46.

Analysts Set New Price Targets

Separately, Wall Street Zen cut Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Coeptis Therapeutics Trading Down 7.0%

The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.25. The company’s 50 day moving average is $12.37 and its 200 day moving average is $12.74. The stock has a market capitalization of $596.07 million, a price-to-earnings ratio of -4.60 and a beta of -0.22.

Coeptis Therapeutics (NASDAQ:ZSQR) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share (EPS) for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.The company had revenue of $0.11 million during the quarter.

Hedge Funds Weigh In On Coeptis Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Yorkville Advisors Global LP bought a new stake in shares of Coeptis Therapeutics in the 3rd quarter worth approximately $140,000. Geode Capital Management LLC lifted its position in Coeptis Therapeutics by 12.6% in the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after purchasing an additional 4,721 shares during the period. Steward Partners Investment Advisory LLC boosted its stake in Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after buying an additional 2,500 shares in the last quarter. State Street Corp boosted its stake in Coeptis Therapeutics by 35.0% during the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in Coeptis Therapeutics in the 4th quarter valued at $259,000. 13.88% of the stock is currently owned by institutional investors.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.